Arrowhead is a clinical stage, targeted therapeutics company developing innovative treatments for obesity, infectious disease, and cancer.
RONDEL™ is engineered to specifically target solid tumors using RNA interference technology.
Based on Arrowhead's Homing Peptide™ technology platform, Adipotide® targets and kills blood vessels that feed white fat tissue.
ARC-520, a combination of Dynamic Polyconjugate™ delivery technology with RNA interference technology targets this global health threat.